Cita APA (7a ed.)
D, M., AR, I., C, L., G, G., L, W., RM, S., . . . Gerrard, G. (2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Journal of Clinical Oncology, 30(3), 232-239.
Cita Chicago Style (17a ed.)
D, Marin, et al. "Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors." Journal of Clinical Oncology 30, no. 3 (2012): 232-239.
Cita MLA (9a ed.)
D, Marin, et al. "Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors." Journal of Clinical Oncology, vol. 30, no. 3, 2012, pp. 232-239.
Precaución: Estas citas no son 100% exactas.